会员注册 | 登录 | 微信快捷登录 QQ登录 微博登录 | 帮助中心 人人文库renrendoc.com美如初恋!
站内搜索 百度文库

热门搜索: 直缝焊接机 矿井提升机 循环球式转向器图纸 机器人手爪发展史 管道机器人dwg 动平衡试验台设计

   首页 人人文库网 > 资源分类 > PDF文档下载

淀粉样变治疗学研究的最新进展.pdf

  • 资源星级:
  • 资源大小:943.05KB   全文页数:5页
  • 资源格式: PDF        下载权限:注册会员/VIP会员
您还没有登陆,请先登录。登陆后即可下载此文档。
  合作网站登录: 微信快捷登录 支付宝快捷登录   QQ登录   微博登录
友情提示
2:本站资源不支持迅雷下载,请使用浏览器直接下载(不支持QQ浏览器)
3:本站资源下载后的文档和图纸-无水印,预览文档经过压缩,下载后原文更清晰   

淀粉样变治疗学研究的最新进展.pdf

clinicaloutcomeofpatientswithadvancednonsmallcelllungcancertreatedwithepidermalgrowthfactorreceptortyrosinekinullnaseinhibitorsJ.IntJCancer,2008,1221126122620.17nullOharaG,KurishimaK,IshikawaH,eta.lKL6andpoorprognosisinNSCLCpatientstreatedwithgefitinibJ.LungCancer,2008,5918187.18nullMatsumuraK,NikiI,TianH,eta.lRadioimmunoscintigraphyofpancreaticcancerintumorbearingathymicnudemiceusing99mtechnetiumlabeledantiKL6/MUC1antibodyJ.RadiatMed,2008,263133139.19nullTokiyaR,HiratsukaJ,YoshidaK,eta.lEvaluationofserumKL6asapredictivemarkerofradiationpneumonitisinpatientswithbreastconservationtherapyJ.IntJClinOnco,l2004,96498502.20nullMatsunoY,SatohH,IshikawaH,eta.lSimultaneousmeasurenullmentsofKL6andSPDinpatientsundergoingthoracicradionulltherapyJ.MedOnco,l2006,2317582.21nullKongFM,AoX,WangL,eta.lTheuseofbloodbiomarkerstopredictradiationlungtoxicityapotentialstrategytoindividualizethoracicradiationtherapyJ.CancerContro,l2008,152140150.编校田媛淀粉样变治疗学研究的最新进展王学文RecentprogressofresearchontherapeuticsofamyloidosisWANGXuewenDepartmentofHematology,NanjingGeneralHospitalofNanjingMilitaryCommand,Nanjing210002,China.nullAbstractnullDuringthepast10to15years,therehasbeensubstantialprogressindevelopingnewtreatmentsforthesystemicamyloidosis.Theseadvanceshaveimprovedpatientoutcomesbuthavealsoraisednewquestionswithdirectclinicalimplications.Forexample,developmentoflessintensivetreatmentsforALamyloidosishasmadelesscertaintheroleofautologousstemcelltransplantation,andnewquantitativeassaysshouldnowallowdeterminationoftheimnullportanceoffullyeliminatingamyloidogeniclightchainproductioninALdisease.Additionally,observationsfromaclinicaltrialinAAamyloidosishavegeneratedhypothesesabouttherelativecontributionsofamyloidprecursorsandmaturefibrilstoamyloidosisassociatedkidneydisease.nullKeywordsnullamyloidosisfreelightchainmelphalan/dexamethasoneMel/DexstemcelltransplantationtargetedtherapyModernOncology2011,190101720176nullUŸK1nullª1015MÏdŸÎxMÍ¥Z|¤LÉŸÉZbƒtÉZ¿ÿÑ€¥B,Œg{Ÿ¥5Ù5bèÂ,®¿ÎxýALÎxM18/ÓÄM±¥T¨‚þ\ç,¹Nž73ñ¥Ñ€b2nullÎxMKD¥KÍýALÎxMdŸÎxMÏK¹Èn„ÉZK¹áÎ3,6b15M¾h¥ÍǹQ¯ÛùP¨ÅEmelphalan,MelFâD¾MPZÃb¾Ehn›†bhØŸ†XHçfo‘âý¥Á3,Ça•Y3iùbS¿1990M}Ïù¥ÍnbÝ4ÅE140200mg/m2­18ÄM±autoSCT,ùܹØXb›†ÓAÐQ‹n¿M’1è¥Ñ€7bV1nulldŸÎxM¥ÕÈn¥Ë˜ÎxM¥Ë˜8‘âƆÊÎxýALnullnullýa/aÉ/GIaPNSaÈF®JFÍ‘âÎxMATTRlM˜JFÍ‘âaPNSºMd˜73˜JFÍ‘âaakaPNSÎxA8AAÓbÎxA8/8»‘âðÎxMAFiblM¥8»‘âðA/aÉApoA1ÎxMApo«‘âA1a/aÉ/GIaPNSaÑ注GI胃肠道PNS外周神经系统AA很罕见,但仍发生在慢性感染a严重痛风a溃疡性结肠炎和转移性肾癌bV2null2Æa2„ÓAÐQ‹¥S52Ænull/24hU‘â0.5g/d,â‘â¹önullÑU܏iC¨12mm,íð¥hV³dnullÉ9É15cm폚fƒ/,ÓbaŸÖ½£Ü1.5žÈKnullÜ/ªëŸ“ÛËîÜhMadžbp¸aLŸüEaа¤2ÏÎí1¥†bÿsÈnullÇË¡¡„_’ªnullk¡„_’ª,WɘŸ¥bИnullÈF®9va1«haÑ,”ahLŸgvÜ_£LaزÆa¤58†˜2Q‹nullÜiWï¨h2mmaÓs”¿ÿ20a2gÿxöS¿ÿ7‚9FæU4„C¨null/24hU‘âh50Àh0.5g/dͳ0.5g/d,ù„ù•bq0Ä‚£Ü¥25nullÉsÈa½´h50,b•UÉvlÀh2cmnullÜÈmÜ.Î¿ÿhnÓAhçfÄÐQ‹›†Q‹çfçÈ£_©Ób„U†XH‘â|Ÿa/FLC1´žÈaÓbFLC´žÈí/ÿ‚†¥Ñ€null†sQ‹ÓbMîs0.5g/dL„h50Uý‚´100mg/d„h50FLC10mg/dl„h50null›†Q‹ªÉZ©V©¥†XH‘âFLC1qsÈnull†sQ‹çQ‹ªÉZÓbM‘â9F50À0.5g/dlUM‘â9F50À‚´200mg/dFLC9F50À10mg/dlnullç훆Q‹a†sQ‹ÉZnullnull2ÿsȹ˜¥Ñ€‹¨FÍHÍM1ýŸP¸5DËžPbALÎxMÑ€®v4Ä„autoSCTÍM1µ§qTAM1MMð0ŸÖÑ€Ú¤8b¸ÎxMÊ/ŒÏwiv4ÅE„SCTHDM/SCTT¹Ê4ŸÑ€¥»BLÍ9bHDM/SCT¥9}Í®g›ÅE0.22mg/kgnulldó¨v4¹Öܾ40mg/dMel/DexÄ4d¹Bñ6bù¡Mel/DexÍyÎô†XHýÁ3„yÎhN7UtBNP,ª€¹ÎxMM1ÿsÈ¥Sb¾Í‚³îôlÄ,‚Á3ÉùA÷¥ÓhbyN,¿HDM/SCTµ²B¥Ñ€Mel/Dex‚þ†a¥©ÊÍbŒ¯¥HDDexÍV{ŸM1¥A8aÓAîïпM„h,ržÓAÐQ‹¥ùK‚üg¾ZÃ¥.ŒÄ6bI¹ALÎxMKD¥ùÍSCT‹¾4ó˜†S¥Ñ€6,µÜ¥M±ÏTRMC¹5,Orûòb1¿Ê4HDM/SCT„Mel/DexT¹KÍ¥MrTCp¤²‚¹H6b3nullALÎxM¥Íùî3.1nullMDex„ASCTÍALÎxM¥1MDex„ASCTALÎxMKW‹¨¥ÕÍnull173nullC}ÖDÐnull2011M01null»19»01ùZE3,6,1011bJaccard©12¡ESÎxM18SCTF29ñϏnullùkÛs¥ALÑ€žHDMel/SCT„Mel/DexFò50èbMel/DexF¥ϔ3iù÷z,13/50èSCTÑ€®¿µ§ùÉZVäsMe,l9赿¶SCTùb¸Ss3inull6ñ¥Ñ€SCTÃAUmbMel/DexFQ‹q68,ϔ3iù56.9ñ,HDM/SCTF22.2ñP0.04bߥ65蛆ÓAÐQ‹qsY¹32„41,Œµs‚A÷bT€²‚ª¹HDM/SCTi‚ª¿Mel/Dexb؂ASCT¤ûòÓAÐQ‹¥m䞣L10bYÈ|Mel/DexT¹AL¥SÍ,Œg›Mel3Ý93sÈ„ŸâÓh¥²B´¤ÿibMMiiAL¥Íª¹g›Mel„DexMDex„HDnullMelAutoSCTSÍbKkMDexÍϤ¥ÓAÐQ‹„3iqË»¿SCT3b‚HDM/SCTÑ€²B9F7mÃ9Fb’³dƒtCHñÙ5A³FIn,¡50èALÎxMÇ37èÛs¥žHDM/SCTF,Ï74¤sÅE200mg/m2bHDM/SCTF¥TAM2412,Ú¿ÎxM†ÏM1ù4146,9bÚµ§qV®¿ÿ¨¥Ñ€µø¥ÿsÈ„i‚˜†HDM/SCTHqܵK6b3.2nullÎxMÑ€AutoSCT†ìSBÎxMÑ€AutoSCT¥†ìS10nullÅSê†ÖxTFECOG8ÿ01null‚ÑVgÿxöNYHAIIIšnullÎx‘âÆ‚ÑV2ñ2nullMnull65ßnullù•bnull0.8ml/s50ml/minnull‰£Énull1.5„ALPnull2nullžÈKnullÑ_°iC„PiªC¨null15mmnullÎx‘âM1¥1öÜhMŒC51ŸnullÎx‘âM1¥ÇËӌC51ŸbÑ€A³˜†††¥SCTS,ísAU††˜†€íTRMbÍ,ÎxMÑ€SCT¥†ìS3c12ñ1¥ÆaLVEFnull45akÛÛïnull50„lêânull90mmHgb¿vƒtSÇ1/3¥Ñ€˜†SCTHqbB,åN¥¡SCT¥ÓAЄ2Q‹¿V33b3.3nullÉZŸALÎxM¥Í37è‚a†SCT¥ÉZŸALÎxM13,MDexµË»¥9Q‹q,ŒQ‹€ϔ3iùÇ22ñb1èQ‹€µ¿ŸâÓhbË»¥xÝϏͥ22èÉZŸÆ¥Ñ€MDexThalQ‹€ϔ3iù24ñ14bMQ,347èALÎxMÑ€51͵Q‹€ϔ3iù70ñ2bƒtùîl2ñ3iM1¥1çy͏ƥi„ñÍ¥Q‹bÎxMÑ€M±˜¥zÊ4V¿ÿSCT¥BbÎxM¥sùd’çÑ€¿çª‚¥Ú²ÿa9Ú¥TroponinT„UÖaîôHV¥A8„hØŸFLC´çUTRM1516bMRIµù¿usÎxM„Úg¨ŸhbE›M±¥Ñ€‚RÄ,y¹VÄ¥‚Q‹VÄaH¥M±,Ä¥Ê4‹InžßSCT¥‚æ•Y,ÂEçÅE†Ø¥,ùÎxM¯–µm¿¿ÿ窥¦{bÁ©‘âcalreticulinÉ©Vr¥ö1Á²†‘â,¤CR¥Ñ€1ÃCRÑ€SCT}cA÷¹Ú,BÕµù¥çªyÍ,Œ³QŸ’ªbV3nullåN¡¥vSCTÑ€¥B3T€è”TRMRR/CR2Q‹ϔ3iùMMel200/hGertz©200731216NA/27264.656/44Skinner©20042701171/33NANR67/33Goodman©2006922337/20NA5.369/31Vesole©20061072732/16263.946/54注TRM治疗相关死亡NA未能得到RR总反应率部分和完全反应CR完全血液学反应NR尚未达到Mel200/减量Mel200mg/m2,减量Mel140or100mg/m23.4nullÎxM¥QSCTÍ‹¨SCTT¹BñÜû“F÷¥ÍgV¿ÿB,5ªQ18SCTasyÄM±„SCTª£ùÍX¨¿ÎxM¥ÍbtϏ¨5ªQM±HDM/SCTP†sÓAÐQ‹Ñ€¹›†ÓAÐQ‹b5ªQ18SCTÏ5›SCTMel200mg/m2,6ñªÃ¤ÓAÐCR¥Ñ€T»QSCT,Mel¹140mg/m217b11¥Ñ€‚¤5ªQSCTî³¥CD34”bTRM¹9,52¥Ñ€¤CR,“»QSCTª¥8bÛ43ñϔ3iùÃrž18b3.5null‚a†SCTSCTª¥£ùÍ‚a¿HDM/SCT¥Ñ€‹InMel/Dexð9}ÍÂÂæÂlenalidomide,Len±9QÜbortenullzomib,Bor¹¥ZÃbMM͍0BorX¨TALÎxM¥„ŸùîbReece©19IùBork¨¿31诟AL,s7ñ4F,BorBÛ1QF0.7a1.0a1.3„1.6mg/m2,4ñ‚4F15èd1a8a15„d22,35Bñ,BÛ2QF0.7a1.0„1.3mg/m2,3ñ‚4F16èd1a4a8„d11,21BñbÓAÐQ‹q5015/30è,“6è20›†Q‹,BorÍžQQ‹¥ϔù¹1.2ñbFKÈn¥ýŸ¹ÇË¡Q‹a¸„ÜdØybKv0s4Òç,1/W„2/WF¥BorBî0s,V¬ÓAÐQ‹b½†46ññ,Ûª4¿³hbBorFALŸÐALXHŸ}G‘â½8M1‘â¥É¥ØeVñµ1,P­0s†_¥FLC20bThalaLen„BorALÎxMµŸ,†0ó¨ÂDex„ÌÿÂb18SCTMelsF100mga140mg200mg/m2,Û²B7MîÍ45èdŸALÎxM£¨Dex/Thalnullùk¥h®TRM„¿ÿQ‹q,²TSCTª9ñÃøìCR¥Ñ€óУùThal„DexÍbTRM¹4.410,69¤s£ùͥрÏ,Thal¥ϔ4¹150mg,16yh¥ÉZÏ£ùÍ,32y0þýŸbSCTªBM,Q‹q78„µøìnull174nullMODERNONCOLOGY,Jannull2011,VOInull19,NOnull01çl¥CR39b¤s£ùÍÑ€¥42¤ÓAÐQ‹¿ÿbϔÛù52ñ,93iq6910b9Bor}9Thal¥nullùùî21,SCTªVߥ22èÑ€ÏCR5èb17è¹ûÃ¥XHŸ}h¤sBor„DexÍbSCTªBMQ‹q94,CR71b¤s£ùͥр92¤¿ÿ,ö”Ñ€AU2Q‹b4nullALÎxMrž›†ÓAÐQ‹¥1ŸALÎxMÍ¥bÁ3\ÎxM‘â¥}XH,V7¸F®Îx‘âÉ›Ÿæ7bŒXHŸ}ó¸Ñ€4¯¥ñ,®NÁ3ÍM1¥A÷ýŸ,7†s„›†ÓAÐQ‹Mm¥M1.¹µK,P¤†sÓAÐQ‹¥fƒ/,³¹¹ÃVY“FÍFÍÜäM’’46bFLC®/l5}†,©ç´s/ÿ¥•Y22bhØŸFLCWsƒ¿8F®,p|ß7™îåžÈ¥ÏWº8bð8»1FLCF®2ýŸl1b7ZÓbFLCi¥1Eçf©çP÷z¥ßÓAÐQ‹a2ÆaÍQ‹„5BbALÎxMÁ3hØŸFLC¥ÐYȆXH}Ñ,2BÑ¥hèÂØ}ØðBØVÁ3FLCi„AL23bØÈÁ3XHŸIgM¬‘â,gVÁ3IgG,hnÁ3IgAÇFLC3bîµ¥ALh謑âÁ3¥A³’ç,’çÁ3FLC¥°¤•Yͦ¥Åç3bt11143040¥ALXHC,Ú¿ÝbALXHYÈÇÁ3XHŸFLC7‚›œ¥Igs0bALÎxMٖIn¹Ÿ,ŒALXHgVrÚ¥cynullclinD1CCND124bt1114„CCND1VVrö•Y5VCaÍQ‹¯¥VŸžØ°Ïbv”ùîÃT›†ÓAÐQ‹„Ñ€3iùÐsˆ2ÿ€WM1Ÿ¥óbgµ¨sÓAÐQ‹²†ÓbFLCiMĥ˻sbvFÛùî|µù¿›†„†sÓAÐQ‹¥M1Ÿ„P¤µô¥ç‹¾Â¹p›†ÓAÐQ‹bß‘âFÐ/ŒV÷°¤¹TÎx‘â¥s˜,V79F¥Üä„hb5nullÎxæ®8žîƒÎxMM1/ÿsÈÏ¥T¨ô8“ùî„54³Æ¥£4U\ÎxM8‘âa|ßÏW8a„8oligomerF®„ýŸ,\PÎxMM1¥2ÿsÈÐÎxð8»í1b8˜„ð8»T¨W¥usç©rµ1Ÿ,yÍÛ_ÎxM3VñV4bV4nulldŸÎxM¥Û_Í6ÍnullnullnullÎxM˘nullnullnullÛ_F}0þAL\Îx8‘âÁ3F‘âAA\Îx8‘âÁ3ÉM±L.ŸTTR,L.Ÿ8»‘âð\Îx8‘âÁ3—£ÖL.ŸTTR8‘âĹ|ߥÏW8Fx1006AL.ŸTTR,ºM˜8‘âĹ|ߥÏW8EprodisateAA,ALÎxð8»¥™îí¾ÍîµË˜Îxð8»¥çŸCPHPCîµË˜Îxð8»¥çŸÛ_F8ALÎx‘âð8»注以上这些对淀粉样变的任何治疗其应用指征尚未经FDA核准bAL淀粉样轻链AA淀粉样A前体TTR运甲状腺蛋白CPHPCR16R2羧基吡咯烷1yl6氧代已酰吡咯烷2羧酸bnullnullEprodisateAAÎxMÑ€/ÿ¥•Y4U\Îx3î¥8‘â„Îxð8»‚oå\PÎxMM1/hM¥VCbEprodisateBÕ{µÈ€¥®s0ÜÖ÷s0,²ÐÖYÿÉÍM»bñÅAAÎxð8»ÐÂGAGW¥MºT¨,ª€\PÎxð8»™îF®¥çŸbKÍ›îAAÎxMeprodisateнÎ4¥vk,C¾0/ÿ¥0ÄqµmT¨,ŒU‘⥆ií•Y25b”ùî„hè¡£üAL„AAÎxhM€ÜÍHDMelAutoSCTh”ÍTNFs8EÌ4‡æ†Finfliximab©ª‘âUÈáιh67,26,–t4³Å\Îx8‘âÁ3¥fƒ/,Û_ALÎxM¥XHŸ}Û_.¡,AAÎxMOÓbÎxA8¥†îbeprodisatei‚•YÓbÎxA8¥£Ü,ñ¹/ÿ,Œ‘âU¥9Fií•Y,V®8žîƒ¥Îxð8»„ÎxM¥‘âU67,26b5k¨eprodisate¥CT³d³1“FLi„5Ø°F’ªbnull•IÓDnull1nullMerliniG,WestermarkP.ThesystemicamyloidosesclearerunnullderstandingofthemolecularmechanismsoffershopeformoreeffecnulltivetherapiesJ.JInternMed,2004,2552159178.2nullMerliniG,PalladiniG.AmyloidosisisacurepossibleJAnnOnco,l2008,19Suppl4iv63iv66.3nullComenzoRL.HowItreatamyloidosisJ.Blood,2009,1141531473157.4nullSekijimaY,WisemanRL,MattesonJ,eta.lThebiologicalandchemicalbasisfortissueselectiveamyloiddiseaseJ.Cel,l2005,12117385.5nullGertzMA,ComenzoR,FalkRH,eta.lDefinitionoforganinnullvolvementandtreatmentresponseinimmunoglobulinlightchainamyloidosisALaconsensusopinionfromthe10thInternationalSymposiumonAmyloidandAmyloidosisJ.AmJHemato,l2005,794319328.6nullDemberLM.ModerntreatmentofamyloidosisUnresolvedquesnulltionsJ.JAmSocNephro,l2009,203469472.7nullLeungN,DispenzieriA,FervenzaFC,eta.lRenalresponseafterhighdosemelphalanandstemcelltransplantationisafavorablenull175nullC}ÖDÐnull2011M01null»19»01ùmarkerinpatientswithprimarysystemicamyloidosisJ.AmJKidneyDis,2005,462270277.8nullJantunenE,ItalaM,LehtinenT,eta.lEarlytreatmentrelatedmortalityinadultautologousstemcelltransplantrecipientsAnanulltionwidesurveyof1482transplantedpatientsJ.EurJHaemanullto,l2006,763245250.9nullCohenAD,ZhouP,ChouJ,eta.lRiskadaptedautologousstemcelltransplantationwithadjuvantdexamethasone/thalidomideforsystemiclightchainamyloidosisResultsofaphaseIItrialJ.BrJHaematol,2007,1392224233.10nullWechalekarAD,HawkinsPN,GillmoreJD.PerspectivesintreatnullmentofALamyloidosisJ.BrJHaemato,l2007,1402365377.11nullPalladiniG,MerliniG.CurrenttreatmentofALamyloidosisJ.Haematologica,l2009,94810441048.12nullJaccardA,MoreauP,LeblondV,eta.lHighdosemelphalanversusmelphalanplusdexamethasoneforALamyloidosisJ.NEnglJMed,2007,3571110831093.13nullLebovicD,HoffmanJ,LevineBM,eta.lPredictorsofsurvivalinpatientswithsystemiclightchainamyloidosisandcardiacinnullvolvementinitiallyineligibleforstemcelltransplantationandtreanulltedwithoralmelphalananddexamethasoneJ.BrJHaemato,l2008,1433369373.14nullPalladiniG,RussoP,LavatelliF,eta.lTreatmentofpatientswithadnullvancedcardiacALamyloidosiswithoralmelphalan,dexamethanullsone,andthalidomideJ.AnnHemato,l2009,882347350.15nullGertzM,LacyM,DispenzieriA,eta.lTroponinTlevelasanexclusioncriterionforstemcelltransplantationinlightchainamyloidosisJ.LeukLymphoma,2008,4913641.16nullKumarS,DispenzieriA,LacyMQ,eta.lSerumuricacidnovelprognosticfactorinprimarysystemicamyloidosisJ.MayoClinProc,2008,833297303.17nullSanchorawalaV,WrightDG,QuillenK,eta.lTandemcyclesofhighdosemelphalanandautologousstemcelltransplantationinnullcreasestheresponserateinALamyloidosisJ.BoneMarrowTransplant,2007,406557562.18nullSchonlandSO,LokhorstH,BuzynA,eta.lAllogeneicandsynnullgeneichematopoieticcelltransplantationinpatientswithamyloidlightchainamyloidosisareportfromtheEuropeanGroupforBloodandMarrowTransplantationJ.Blood,2006,107625782584.19nullReeceDE,SanchorawalaV,HegenbartU,eta.lWeeklyandtwiceweeklybortezomibinpatientswithsystemicALamyloidosisrenullsultsofaphase1doseescalationstudyJ.Blood,2009,114814891497.20nullSitiaR,PalladiniG,MerliniG.BortezomibinthetreatmentofALamyloidosistargetedtherapyJHaematologica,2007,921013021307.21nullLandauHJ,HassounH,ElizabethH,eta.lAdjuvantbortezomibanddexamethasonefollowingriskadaptedmelphalanandstemcelltransplantinpatientswithlightchainamyloidosisALJ.JClinOnco,l2009,2715S8540.22nullDispenzieriA,KyleR,MerliniG,eta.lInternationalMyelomaWorkingGroupguidelinesforserumfreelightchainanalysisinmultiplemyelomaandrelateddisordersJ.Leukemia,2009,232215224.23nullCohenAD,ZhouP,XiaoQ,eta.lSystemicALamyloidosisduetononHodgkinslymphomaanunusualclinicopathologicassonullciationJ.BrJHaemato,l2004,1243309314.24nullBochtlerT,HegenbartU,CremerFW,eta.lEvaluationofthecytogeneticaberrationpatterninamyloidlightchainamyloidosiscomparedwithmonoclonalgammopathyofundeterminedsignifinullcancerevealscommonpathwaysofkaryotypicinstabilityJ.Blood,2008,111947004705.25nullDemberLM,HawkinsPN,HazenbergBP,eta.lEprodisateforthetreatmentofrenaldiseaseinAAamyloidosisJ.NEnglJMed,2007,3562323492360.26nullRavindranJ,ShenkerN,BhallaAK,eta.lCasereportResponseinproteinuriaduetoAAamyloidosisbutnotFeltyssyndromeinapatientwithrheumatoidarthritistreatedwithTNFalphablocknulladeJ.RheumatologyOxford,2004,435669672.编校田媛甲状腺癌易感基因的研究进展迟晓云,焦淑贤ResearchprogressionofthyroidcarcimomaspredisposinggenesCHIXiaoyun,JIAOShuxianInstituteofTransfusionMedicine,QingdaoBloodCenter,Qingdao266071,China.nullAbstractnullThyroidcarcimomaisacomplexdeseaseparticipatedofmultiplefactors.Whichetiopathogenisisandinnullvasionmechanismisunknown.Investigationindicatedthattheinteractionofenvironmentalfatoranddescentpredisponullsingfatorwasmajoritycarcinomasetiopathogenisis,anddescentpredisposingfatorwasmoreimportant.Thisarticlenulllà°ùnullnull20100315nullÁnullnull›g2uS/Z9ÃÁùI|2009521GGnullT€†Ênullnull›gϏÓ_{ÓDÐùîî,öênull›null266071nullT€eºnullnullþk1980,o,öꯞ¦,þýD,«V,ö1VYçfL.ÐùîbEmailxy.chi163.comnull176nullMODERNONCOLOGY,Jannull2011,VOInull19,NOnull01

注意事项

本文(淀粉样变治疗学研究的最新进展.pdf)为本站会员(abaodong)主动上传,人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知人人文库网([email protected]),我们立即给予删除!

温馨提示:如果因为网速或其他原因下载失败请重新下载,重复下载不扣分。

copyright@ 2015-2017 人人文库网网站版权所有
苏ICP备12009002号-5